Wellington Management Group LLP Has $14.29 Million Holdings in Pacira BioSciences, Inc. $PCRX

Wellington Management Group LLP increased its position in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) by 17.8% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 563,458 shares of the company’s stock after purchasing an additional 85,075 shares during the period. Wellington Management Group LLP owned about 1.41% of Pacira BioSciences worth $14,295,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of PCRX. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Pacira BioSciences by 4.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 27,242 shares of the company’s stock worth $677,000 after buying an additional 1,165 shares in the last quarter. Goldman Sachs Group Inc. boosted its position in shares of Pacira BioSciences by 49.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,104,796 shares of the company’s stock valued at $27,454,000 after acquiring an additional 367,869 shares in the last quarter. Strs Ohio bought a new stake in Pacira BioSciences in the first quarter valued at about $75,000. Marshall Wace LLP bought a new stake in Pacira BioSciences in the second quarter valued at about $4,550,000. Finally, Sei Investments Co. raised its position in Pacira BioSciences by 35.3% in the second quarter. Sei Investments Co. now owns 25,357 shares of the company’s stock worth $606,000 after purchasing an additional 6,609 shares in the last quarter. 99.73% of the stock is currently owned by institutional investors and hedge funds.

Pacira BioSciences Price Performance

Shares of NASDAQ:PCRX opened at $26.35 on Tuesday. The company has a quick ratio of 3.94, a current ratio of 5.04 and a debt-to-equity ratio of 0.54. The firm has a market cap of $1.05 billion, a P/E ratio of 75.29 and a beta of 0.26. Pacira BioSciences, Inc. has a 12 month low of $18.80 and a 12 month high of $27.66. The company’s 50-day moving average price is $25.45 and its two-hundred day moving average price is $24.04.

Pacira BioSciences (NASDAQ:PCRX) last announced its earnings results on Tuesday, August 4th. The company reported $0.73 earnings per share for the quarter, topping analysts’ consensus estimates of $0.65 by $0.08. Pacira BioSciences had a net margin of 1.96% and a return on equity of 9.68%. The company had revenue of $192.40 million during the quarter, compared to the consensus estimate of $191.06 million. During the same period in the previous year, the firm posted $0.74 earnings per share. The company’s revenue was up 6.2% on a year-over-year basis. As a group, research analysts forecast that Pacira BioSciences, Inc. will post 1.98 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts recently commented on the company. Wall Street Zen downgraded Pacira BioSciences from a “strong-buy” rating to a “buy” rating in a research report on Sunday, August 16th. Royal Bank Of Canada upped their target price on shares of Pacira BioSciences from $24.00 to $25.00 and gave the stock a “sector perform” rating in a report on Wednesday, August 5th. HC Wainwright restated a “buy” rating and issued a $38.00 price target on shares of Pacira BioSciences in a research report on Wednesday, July 1st. Truist Financial began coverage on shares of Pacira BioSciences in a research note on Monday, August 17th. They set a “buy” rating and a $30.00 price objective on the stock. Finally, Needham & Company LLC raised their price objective on shares of Pacira BioSciences from $32.00 to $33.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. Three analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $30.20.

Insider Activity at Pacira BioSciences

In related news, insider Jonathan Slonin sold 3,040 shares of the business’s stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $23.23, for a total value of $70,619.20. Following the completion of the transaction, the insider owned 216,384 shares in the company, valued at $5,026,600.32. The trade was a 1.39% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Lauren Riker sold 6,115 shares of the stock in a transaction on Thursday, June 11th. The shares were sold at an average price of $23.50, for a total value of $143,702.50. Following the completion of the transaction, the senior vice president owned 62,284 shares in the company, valued at $1,463,674. The trade was a 8.94% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 6.40% of the company’s stock.

Pacira BioSciences Profile

Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid, non-addictive pain management and regenerative health solutions. The company’s flagship product, EXPAREL, is a bupivacaine liposome injectable suspension designed to provide long-lasting postsurgical analgesia. EXPAREL is used by clinicians across a broad range of surgical procedures to reduce reliance on opioid medications and to help manage acute postoperative pain.

In addition to its marketed offering, Pacira maintains an active pipeline of investigational products aimed at addressing unmet needs in pain management and inflammation control.